FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer

Inclusion Criteria: 1. Older than 19 years old and younger than 75 years old 2. Pathologically confirmed gastric cancer 3. Inoperable stage at diagnosis 4. experienced diseases progression in first line palliative chemotherapy 5. ECOG performance status 0 or 1 6. Adequate renal function (serum creatinine \< 1.5 mg/dL or calculated creatinine clearance ≥ 60 ml/min) 7. Adequate liver function (total bilirubin \< 1.5 X the upper limits of normal (ULN), AST and ALT \<3 X UNL, and alkaline phosphatases \< 3 X ULN or \< 5 x ULN in case of liver involvement) 8. Adequate BM function (WBC ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl, platelet count ≥ 100,000/µl) 9. Subjects who given written informed consent after being given a full description of the study Exclusion Criteria: 1. double primary cancer other than gastric cancer 2. history of palliative radiation therapy 3. Pregnant or on breast feeding 4. Neuropathy grade \> 3 5. Active infection 6. Symptomatic cardiopulmonary diseases 7. Active hepatitis of liver cirrhosis 8. Impaired renal function 9. Impaired psychologic bone marrow function 10. Psychologic disorder, Severe neurologic disorder. 11. hypersensitivity to chemotherapeutic agent